Sign in
Not yet recruitingNo phase

Breakthrough Platform Trial for PCAS

Key facts

Who runs it
Kagawa University
Where
Japan12 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
People taking part
630 people, planned
Started
1 Sept 2026
Expected to end
30 Jun 2031
Type of study
Interventional, 2 groups
Treatments tested
  • Head Positioning
  • Temperature Control
Record updated
17 August 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 33 criteriaShow less

Who can take part

  • Master Platform Eligibility:
  • Adult patients aged 18 years or older
  • Return of spontaneous circulation after cardiac arrest
  • Persistent coma after return of spontaneous circulation (GCS motor score <6)
  • Requirement for intensive care management; Head Positioning Domain Eligibility:
  • Non-traumatic out-of-hospital or in-hospital cardiac arrest
  • Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable); Temperature Control Domain Eligibility:
  • Initial non-shockable cardiac arrest rhythm
  • Systolic blood pressure ≥80 mmHg or mean arterial pressure ≥65 mmHg (fluid resuscitation and vasopressor use permitted; transient hypotension recoverable within 20-30 minutes is acceptable)
  • Ability to initiate temperature control therapy within 240 minutes after return of spontaneous circulation

Who cannot take part

  • Cardiac arrest due to intracranial hemorrhage, subarachnoid hemorrhage, cerebral infarction, acute aortic dissection, or terminal cancer (including suspected cases)
  • Severe chronic obstructive pulmonary disease requiring home oxygen therapy
  • Traumatic cardiac arrest
  • Master Platform Exclusion:
  • Refusal of intensive care management
  • Extracorporeal cardiopulmonary resuscitation (ECPR)
  • Pregnancy or possible pregnancy
  • Poor pre-arrest neurological function (CPC 3-4) or poor overall functional status (OPC 3-4)
  • Pre-existing do-not-attempt-resuscitation (DNAR) order
  • Expected early death
  • Inability to obtain consent from a legally acceptable representative or the participant
  • Enrollment judged inappropriate by the investigator; Head Positioning Domain Exclusion:
  • Body temperature <30°C on hospital arrival
  • Refusal of consent for participation in the head positioning domain
  • Enrollment judged inappropriate by the investigator
  • Patients using Impella® (a percutaneous mechanical circulatory support catheter) at the time of ICU admission
  • Patients using an intra-aortic balloon pump (IABP) at the time of ICU admission
  • Patients for whom feedback-controlled device-based temperature management or fever prevention is not being performed and is not planned at the time of ICU admission; Temperature Control Domain Exclusion:
  • rCAST <4.5
  • rCAST ≥17.0
  • Body temperature <30°C on hospital arrival
  • Refusal of consent for participation in the temperature control domain
  • Enrollment judged inappropriate by the investigator

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this platform clinical trial is to evaluate whether specific post-cardiac arrest care strategies can improve neurological recovery and survival in adult patients who remain comatose after return of spontaneous circulation (ROSC) following cardiac arrest and require intensive care management.

Read full original descriptionShow less

This multicenter cluster-randomized crossover platform trial (BPT-PCAS) evaluates post-cardiac arrest care strategies within a shared master protocol structure. Participating hospitals are randomized at the institutional level to predefined treatment strategies for fixed study periods and subsequently cross over to alternative strategies according to a predefined allocation schedule.

The platform is designed to accommodate multiple independent intervention domains, each evaluating a different post-cardiac arrest care strategy under shared eligibility criteria, infrastructure, data management systems, and follow-up procedures. Participants may be enrolled in one or more active intervention domains according to platform availability and eligibility.

Participants will receive the post-cardiac arrest care strategy assigned to their participating hospital during the study period while otherwise undergoing standard intensive care management according to local practice and study protocols.

Participants will be followed for neurological outcomes including modified Rankin Scale (mRS), mortality, and safety outcomes at hospital discharge, 30 days, and 90 days after hospital admission.

The 2 groups in the trial

  • Head Positioning Strategy (near-supine vs head elevation)Treatment being tested

    Participants receive institutionally assigned post-cardiac arrest head positioning strategies according to the cluster-randomized crossover platform protocol, including head elevation (30°-45°) or near-supine positioning (0°-10°).

    Treatment: Head Positioning

  • Temperature Control Strategy (hypothermia vs normothermia)Treatment being tested

    Participants receive institutionally assigned post-cardiac arrest temperature control strategies according to the cluster-randomized crossover platform protocol, including targeted hypothermia (33-34°C) or normothermia/fever prevention strategies (36-37.5°C).

    Treatment: Temperature Control

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Breakthrough Platform Trial for Post Cardiac Arrest Syndrome
Record updated
17 August 2026